.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF06_Cemiplimab.Cemiplimab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF06_Cemiplimab.Cemiplimab| name: | Cemiplimab |
| ATC code: | L01FF06 | route: | intravenous |
| n-compartments | 2 |
Cemiplimab is a human monoclonal antibody designed to bind to the programmed death-1 (PD-1) receptor and block its interaction with PD-L1 and PD-L2, thereby enhancing T-cell responses. It is approved for the treatment of cutaneous squamous cell carcinoma, non-small cell lung cancer, and basal cell carcinoma.
Pharmacokinetic model in adult cancer patients. Data represent population PK analysis of cemiplimab in patients with solid tumors.
Nguyen, JH, et al., & Al-Huniti, N (2022). Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer. CPT: pharmacometrics & systems pharmacology 11(11) 1458–1471. DOI:10.1002/psp4.12855 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36251220
Yang, F, et al., & DiCioccio, AT (2021). Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies. Journal of pharmacokinetics and pharmacodynamics 48(4) 479–494. DOI:10.1007/s10928-021-09739-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/33728546
Paccaly, AJ, et al., & Rischin, D (2021). Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis. Advances in therapy 38(5) 2365–2378. DOI:10.1007/s12325-021-01638-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33768419